AI Diagnostics Growth IMVARIA has FDA-authorized AI tools for ILD and IPF (Fibresolve), indicating a proven regulatory pathway and clinical credibility which can be leveraged to expand adoption among pulmonology clinics, hospitals, and reference labs seeking compliant AI diagnostic support.

Clinical Partnerships Active collaborations with Mayo Clinic and ongoing NIH SBIR funding signal strong credibility and potential for co-developed biomarkers; target institutions with large imaging and pathology datasets to accelerate AI biomarker programs in oncology and pulmonology.

Multi-site Validation Recent multi-site clinical experience with AI diagnostic service demonstrates scalable adoption; sales strategy can focus on health systems and academic centers seeking validated, non-invasive adjunctive tools for suspected ILD/IPF.

SBIR Funding Signal NIH SBIR Phase I grant indicates government-supported market validation and potential for further grants; explore opportunities with research groups and grant-enabled pilots to expand AI biomarker offerings across oncology and immunology.

Tech & Platform Readiness Robust tech stack including AWS, Google Cloud, Webflow and advertising platforms suggests readiness for enterprise deployments and scalable SaaS integrations; target cloud-enabled clinics, digital health platforms, and system integrators for seamless implementation.